The Pulse Newsletter Expert heart health, in plain English. Fortnightly, from our clinicians. Subscribe →

Prof. Peter Barlis

Professor Peter Barlis (MBBS, MPH, PhD, FESC, FACC, FSCAI, FRACP) is an Interventional Cardiologist and the founding editor of Heart Matters. With expertise in coronary artery disease, advanced cardiac imaging, and interventional cardiology — and fellowships of the European Society of Cardiology, the American College of Cardiology, and the Royal Australasian College of Physicians — he brings the highest level of clinical authority to everything published on this site. Heart Matters was founded on Professor Barlis's belief that patients who understand their condition are less frightened and better equipped to make decisions about their care. Every article on this site reflects that commitment.

CoQ10 and Your Heart: What the Evidence Actually Shows

heartmatters.com 51

CoQ10 is a widely used supplement, especially among people on statins, but the evidence is more mixed than the marketing suggests. Here is what it can and can’t do, who might benefit, and the interactions that matter if you are on a blood thinner.

Vascepa and Vazkepa: What This Prescription Omega-3 Actually Does

Vascepa Vazkepa
Key Points

  • Vascepa and Vazkepa are two brand names for the same prescription medication, icosapent ethyl, a highly purified form of the omega-3 fatty acid EPA. The medication is sold as Vascepa in the United States and as Vazkepa across Europe, the United Kingdom, Australia and other markets. Neither is the same as an over-the-counter fish oil supplement.
  • It is prescribed as an add-on for people already taking a statin who have raised triglycerides and are at high risk of a heart attack or stroke. It is not a replacement for a statin.
  • The REDUCE-IT trial found it reduced the risk of serious cardiovascular events by 25% in this group, a result that changed guidelines in several countries.
  • The dose is two 998 mg capsules twice daily, four capsules a day in total, always taken with a meal. Food is essential for proper absorption.
  • The two side effects to know about are a small increased risk of atrial fibrillation and an increased tendency to bleed. Tell your doctor and pharmacist about every other medication you take. Never stop without speaking to your cardiologist first.

For many years, cardiologists recommended fish oil capsules to patients with high triglycerides, and the evidence was modest at best. Then in 2018 a major clinical trial changed the conversation.

The REDUCE-IT trial reported that a specific prescription omega-3 medication reduced the risk of heart attack, stroke, and cardiovascular death in high-risk patients already on statin therapy. The results prompted cardiologists to rethink how they managed this group. This article explains what the medication is, who it is for, how it works, and what to expect if you have been prescribed it.

What Are Vascepa and Vazkepa?

Vascepa and Vazkepa are two brand names for the same medication, icosapent ethyl, a highly purified, prescription-strength form of EPA, one of the omega-3 fatty acids found in oily fish. It was first approved in the United States, where the REDUCE-IT trial was run, and is sold there as Vascepa. In Europe, the United Kingdom, Australia and a number of other markets it is sold as Vazkepa. The active ingredient and the dose are identical, so everything in this article applies equally to both.

What makes this medication different from a standard fish oil supplement is that it contains only EPA, with no DHA, and it is manufactured to a far higher standard of purity. That distinction matters clinically, and we will come back to it in the comparison section below.

How Does It Work?

The medication lowers blood triglycerides, a type of fat that circulates in the bloodstream. At the full prescribed dose it typically reduces triglycerides by around 20 to 30%. The cardiovascular benefit seen in REDUCE-IT was larger than triglyceride lowering alone could explain, and researchers believe several additional mechanisms are involved.

Lowers triglycerides

Reduces this blood fat by about 20 to 30% at the full prescribed dose.

Reduces inflammation

EPA enters blood vessel walls, where it may cool the chronic inflammation that drives arterial plaque.

Stabilises plaque

May make existing fatty deposits more stable and less likely to rupture, the event that triggers most heart attacks.

Reduces platelet stickiness

Platelets are the cells that clump to form clots. Making them less sticky may reduce the risk of a dangerous blockage.

The precise contribution of each pathway is still being studied. You can read more about how inflammation drives heart disease in a separate article.

Who Is It Prescribed For?

This medication is not for everyone. It is mainly used to lower heart risk in people who are already taking a statin but still have raised triglycerides, and who are at high risk because they have already had heart trouble or have diabetes alongside other risk factors. In some countries it is also used to bring down very high triglyceride levels. It is taken alongside a statin, not instead of one.

The exact rules for who can be prescribed it differ from one country to another, and they change over time. So the only reliable answer to “is this right for me?” comes from your own doctor, who can weigh it against your personal situation. Always check with your cardiologist or GP before assuming it does or does not apply to you.

This is not a fish oil capsule from the supermarket. It is a purified, prescription medicine with trial evidence behind it, for a specific group of high-risk patients already on a statin.

Prof. Peter Barlis, Interventional Cardiologist

The REDUCE-IT Trial

The evidence behind this medication comes largely from one landmark clinical trial.

8,179
Patients across 11 countries
4.9
Years average follow-up
25%
Reduction in serious heart events vs placebo
2018
Published in the New England Journal of Medicine

All participants were on stable statin therapy with raised triglycerides. Roughly 70% had already had cardiovascular disease, while the rest had diabetes and additional risk factors. They were randomly assigned to receive either icosapent ethyl or a placebo, a dummy capsule with no active ingredient.

The result was a 25% reduction in serious heart events, a group that included heart attacks, strokes, cardiovascular deaths, and hospital admissions for severe chest pain. Put another way, several fewer people in every hundred had a serious heart event over about five years. In a population already at elevated risk, that is a meaningful difference.

25%
lower risk of serious cardiovascular events in high-risk patients on statin therapy, a result that prompted guideline updates in several countries.
REDUCE-IT trial, New England Journal of Medicine, 2018

How to Take It

The approved dose is two 998 mg capsules twice daily, four capsules a day in total, taken with meals. Food is not optional here. The medication is far better absorbed when taken with food, so the capsules should always be swallowed whole with or just after a meal, never crushed or chewed.

Morning
2 x 998 mg capsules
Take with your morning meal. Swallow whole. Do not crush or chew.
Evening
2 x 998 mg capsules
Take with your evening meal. Storing capsules in the fridge can reduce any fishy aftertaste.

This is a long-term medication whose benefits accumulate over time. If you miss a dose, take your next one as normal with your next meal, and do not double up. The dose and duration are individual, and only your cardiologist can advise what is right for you. Never stop taking it without speaking to your cardiologist first.

Side Effects to Know About

The medication is generally well tolerated, and most people take it without significant problems. Two effects deserve specific attention.

Atrial fibrillation

REDUCE-IT found a small increase in atrial fibrillation, the most common abnormal heart rhythm. The absolute increase was modest. Worth discussing with your cardiologist if you have a history of AF or palpitations.

Increased bleeding tendency

It reduces platelet stickiness, which can increase the tendency to bleed. In the trial, bleeding events were modestly more common than with placebo (around 12% versus 10%), and the risk was greater in people also taking blood-thinning medications such as aspirin, clopidogrel, or warfarin. Tell your doctor and pharmacist about every medication you take.

Other reported effects include constipation, swelling of the hands, feet, or legs, joint or muscle pain, gout, and a fishy aftertaste. Serious reactions are uncommon. Because this is a relatively new medicine, it remains under additional safety monitoring in many countries, and any side effects can be reported to your doctor or your national medicines regulator.

How It Differs From Standard Fish Oil

Many patients ask whether this is just an expensive fish oil capsule. It is not, and the difference is clinically important.

Vascepa / Vazkepa (prescription) Standard fish oil (over the counter)
Active ingredient EPA only, highly purified Mix of EPA and DHA, typically 30 to 40% omega-3
Manufacturing standard Pharmaceutical grade Supplement grade
Contains DHA No Yes
Effect on LDL cholesterol Neutral to slightly favourable DHA may raise LDL slightly
Cardiovascular trial evidence REDUCE-IT: 25% fewer serious heart events No comparable outcome data
Suitable for vegetarians No, fish-derived EPA and capsule shell Most are not, check labelling

The absence of DHA is deliberate. DHA may raise LDL cholesterol slightly, potentially offsetting some of the benefit, which may be part of why this medication performed differently from standard fish oil in trials. It is worth being clear about one practical point: because both the EPA and the capsule shell are fish-derived, the medication is not suitable for vegetarians, vegans, or people who avoid fish products for religious or cultural reasons, and there is currently no approved vegetarian alternative with the same evidence. If this applies to you, raise it with your cardiologist rather than simply stopping.

Cost and Availability

Because this is a prescription medication rather than a supplement, how much you pay depends heavily on where you live and how your healthcare system works. In some countries it is subsidised through a national scheme or covered by insurance for patients who meet specific criteria, which can reduce the cost substantially. In others it is paid for privately and can be expensive. Approval status and the exact eligibility rules also differ from country to country, and they change over time. The reliable approach is to ask your cardiologist or pharmacist about availability, eligibility, and cost where you live, rather than relying on a figure you read online.

Common Questions

Can I replace my statin with it? No. It works alongside a statin, not instead of one, and all the trial evidence comes from patients already on statin therapy.

Will it show up on a blood test? Yes. Your triglyceride level will fall, and your cardiologist will likely recheck your lipids a few months after starting to confirm it is working as expected.

How long until it works? The triglyceride-lowering effect appears within weeks, but the cardiovascular benefit builds over years of consistent use. This is a medicine for the long term, not a short course.

Heart Matters Resource

When in Doubt, Get Checked Out

If you have raised triglycerides and established heart risk, whether a medication like this fits your care is a conversation worth having. Your cardiologist can weigh it against the rest of your treatment plan.

Read: When in Doubt, Get Checked Out →

Conclusion

For a specific group of patients, those already on a statin with raised triglycerides and significant heart risk, the REDUCE-IT evidence shows that icosapent ethyl, whether dispensed as Vascepa or Vazkepa, can reduce the chance of a serious cardiovascular event. It is not a treatment for everyone, and it is not a substitute for the rest of your care.

If you have been prescribed it, take it consistently with meals, keep your pharmacist informed about all your other medications, and attend your regular blood test appointments. That is what gives this medication the best chance of working well for you.

And if you have read this wondering whether it might help you, the most useful next step is simply to ask. Whether this medication is suitable for you depends on your own health, your other medicines, and your level of risk, and only a doctor who knows your history can make that call. Always check with your cardiologist or GP before starting, stopping, or changing any treatment.

Related Reading

ApoB Explained: What It Measures and Why LDL Still Matters

apoB
Key Points

  • ApoB is a single protein that sits on the surface of every cholesterol particle capable of causing plaque, so an apoB result is effectively a headcount of all the particles that can harm your arteries.
  • A standard LDL cholesterol result measures the cholesterol carried inside your particles, not how many particles there are. Most of the time the two agree, but in some people they do not.
  • When LDL cholesterol looks reassuring but apoB is high, this mismatch (called discordance) can reveal hidden risk that a routine cholesterol panel misses.
  • Strong evidence supports apoB as an accurate marker of cardiovascular risk, particularly in people with high triglycerides, type 2 diabetes, or metabolic syndrome.
  • ApoB does not replace your LDL, triglycerides, or lipoprotein(a) results. Each tells you something the others cannot, and the best assessment uses them together.
  • No single number captures your risk. Heart disease is multifactorial, so blood pressure, diabetes, smoking, weight, and family history all matter alongside your lipids. Investigations such as a calcium score add another layer, and whether to add apoB is a conversation worth having with your cardiologist.

There is a lively and sometimes heated debate online about cholesterol. One vocal group argues that the LDL cholesterol number most of us have measured for decades is almost beside the point, and that a different number, apolipoprotein B, or apoB, is the one that truly predicts heart disease. If you have come across this argument and felt unsure who to believe, you are not alone.

The truth, as is so often the case in medicine, sits between the two extremes. ApoB is a genuinely valuable measurement, and the science behind it is sound. It is also not a magic number that makes everything else obsolete. This article explains what apoB actually is, why it can outperform a standard cholesterol result, and how to think about whether it belongs in your own blood tests.

What Is ApoB, Exactly?

To understand apoB, it helps to picture how cholesterol travels through your blood. Cholesterol is a fatty substance, and fat does not dissolve in water. So your body packages cholesterol inside tiny spherical particles that can move through the bloodstream. The particles that drive atherosclerosis, the gradual furring of the arteries, include LDL (low density lipoprotein) and a few close relatives.

Here is the key fact. Every one of these harmful particles carries exactly one molecule of a protein called apolipoprotein B on its surface. One particle, one apoB. This includes LDL, VLDL, IDL, and even lipoprotein(a). So when a laboratory measures your apoB level, it is effectively counting the total number of particles in your blood that are capable of lodging in your artery wall and forming plaque.

Why Counting Particles Can Beat Measuring Cholesterol

A standard lipid panel reports your LDL cholesterol, which sounds like it should tell you everything. But LDL cholesterol measures the amount of cholesterol carried inside your LDL particles. It does not measure how many particles you have.

This distinction matters because particles vary in size. Some people carry a smaller number of large, cholesterol-rich particles. Others carry a large number of small, cholesterol-poor particles. Two people can have an identical LDL cholesterol result while one has far more circulating particles than the other. Since it is the particles themselves that burrow into the artery wall, the person with more particles carries more risk, even though their cholesterol number looks the same.

A useful way to picture it: imagine traffic on a motorway. LDL cholesterol tells you the total weight of cargo being carried. ApoB tells you how many vehicles are on the road. If your arteries are the road, it is the number of vehicles, not the total cargo, that determines how often something collides with the wall.

One protein per particle

Every harmful cholesterol particle carries a single apoB protein, so your apoB level counts every particle that can cause plaque.

Cargo versus headcount

LDL cholesterol measures the cargo carried inside particles. ApoB counts the particles themselves, which is what damages the artery wall.

Why the gap matters

When particle count is high but cholesterol per particle is low, your LDL result can look fine while your true risk is not.

The family of particles apoB counts

ApoB does not just count LDL. It tags several related particles, each of which can contribute to plaque. This is part of why a single apoB result can be so informative: it captures the whole atherogenic family in one number.

LDL

Low density lipoprotein. The most familiar and most numerous of the harmful particles, and the main driver of plaque in most people.

VLDL and IDL

Larger, triglyceride-rich particles and their remnants. They become more important when triglycerides are high.

Lipoprotein(a)

An LDL-like particle with an extra protein attached. Largely inherited, and counted within apoB but not separately identified by it.

Each of these carries one apoB protein, so they are all captured in your total. What apoB cannot do is tell you the breakdown. It will not reveal, for instance, whether a high count is driven by ordinary LDL or by an inherited excess of Lp(a). That is one reason the individual tests retain their value, a point we return to below.

When LDL Cholesterol and ApoB Disagree

Most of the time, your LDL cholesterol and your apoB tell the same story. When both are high, or both are low, doctors call this concordance, and a standard cholesterol panel serves you perfectly well.

The interesting and clinically important situations are the mismatches, known as discordance. This is when your LDL cholesterol looks acceptable but your apoB is high, signalling many small particles quietly carrying on their work. In this scenario, a reassuring cholesterol result can give false comfort. A large 2024 review of 15 studies involving nearly 600,000 people found that apoB was a more accurate marker of risk than LDL cholesterol in every discordance study examined.

Who is most likely to be discordant

You are more likely to have a meaningful gap between your LDL cholesterol and your apoB if you have any of the following: high triglycerides, type 2 diabetes, metabolic syndrome, central weight gain around the abdomen, or a pattern of small dense LDL particles. People in these groups can have a deceptively normal LDL cholesterol while their particle count, and their risk, runs higher. This is precisely the group in which apoB adds the most.

What the Evidence Actually Shows

The case for apoB is strong, and it is worth being clear about what the research does and does not say.

On the supportive side, apoB has performed consistently well as a predictor of heart attack and stroke, often edging out both LDL cholesterol and non-HDL cholesterol, particularly in people whose results are discordant. Because it counts particles directly, it is less affected by the variations in particle size that can distort a standard cholesterol reading. For people with diabetes or high triglycerides, this advantage is most pronounced.

On the cautious side, this does not mean LDL cholesterol is worthless. Far from it. Lowering LDL cholesterol remains the single most trial-tested intervention in all of preventive cardiology. Decades of randomised trials, including the trials that established statins and newer agents such as PCSK9 inhibitors, were built on LDL cholesterol as the target, and the benefit of lowering it is beyond dispute. The online voices declaring LDL cholesterol irrelevant overstate the case considerably.

Why LDL, Triglycerides, and Lp(a) Still Matter

The enthusiasm for apoB has, in some corners of the internet, tipped into dismissing the numbers we have relied on for years. That is a mistake. Each of the established measurements tells you something apoB alone does not, and a good lipid assessment uses them together.

LDL cholesterol

LDL cholesterol is not a flawed or outdated number. It is the most thoroughly validated treatment target in cardiology, and every major guideline still places it at the centre of care. The reason is simple: when we lower LDL cholesterol in clinical trials, heart attacks and strokes fall in proportion, reliably and repeatedly. ApoB refines how we interpret LDL cholesterol in certain people. It does not unseat it. If you are tracking one number over time to see whether your treatment is working, LDL cholesterol remains an entirely sensible choice.

Triglycerides

Triglycerides are a separate and valuable piece of the puzzle. A raised triglyceride level is one of the clearest signals that your LDL cholesterol and apoB may be discordant, because high triglycerides tend to accompany the small, dense, numerous particles that apoB picks up. Triglycerides also respond strongly to lifestyle, which makes them a useful and motivating number to watch. Diet matters here, and the evidence supporting the Mediterranean diet and omega-3 fats is particularly relevant for people with elevated triglycerides.

Lipoprotein(a)

Lipoprotein(a), or Lp(a), deserves its own place on the test request entirely. It is largely inherited, it changes very little over a lifetime, and a single measurement tells you whether you carry this extra, independent layer of risk. While apoB does count Lp(a) particles among its total, it cannot tell you how much of your risk comes specifically from Lp(a), which is why a dedicated Lp(a) test remains worthwhile in its own right. For many people this is a once-in-a-lifetime measurement that meaningfully changes how aggressively their other risk factors should be managed.

What Does a Statin Do to Your ApoB?

This is a question worth answering directly, because it is one of the most useful things to understand about apoB in practice. Statins lower apoB substantially, typically by somewhere in the range of a quarter to nearly half, broadly in step with how much they lower LDL cholesterol. Adding ezetimibe or a PCSK9 inhibitor brings it down further still. So if you are already on treatment, your apoB is very likely already falling alongside your other numbers.

There is one important exception, and it is the reason apoB does not make the individual tests redundant. Statins do very little to lipoprotein(a). Someone can take a statin, watch their LDL cholesterol and apoB fall nicely, and still carry a high inherited Lp(a) that the treatment has barely touched. This is exactly why measuring Lp(a) at least once, separately, remains worthwhile even for people whose apoB looks well controlled.

ApoB Is One Piece of a Multifactorial Picture

Perhaps the most important point in this whole discussion is the one the online debate tends to forget. Cardiovascular disease is multifactorial. No single number, however good, captures your risk on its own, and apoB is no exception.

Your overall risk is shaped by a web of factors that interact with one another. These include your blood pressure, whether you have type 2 diabetes or features of metabolic syndrome, whether you smoke, your weight and waist measurement, your family history, your level of inflammation, and your age. A person with a perfect apoB but uncontrolled blood pressure and a smoking habit is not low risk. Conversely, a moderately raised apoB carries very different weight in an otherwise healthy 45-year-old than in someone with diabetes and a strong family history.

This is why fixating on any one marker, apoB included, can be misleading. The most useful approach is the one your cardiologist actually uses: weighing your lipids alongside every other modifiable factor. Two of the most powerful of those, smoking and high blood pressure, are entirely separate from your cholesterol particles and yet enormously important. You can read a fuller account in our overview of cardiovascular risk factors.

The Role of Investigations

Blood markers tell you about risk. Imaging can tell you what is actually happening in your arteries, and the two together are far more informative than either alone.

The coronary calcium score is the investigation patients most often ask about, and it can be confusing, so it is worth being clear. A calcium score does not measure your cholesterol or your particle count. It measures calcified plaque that has already formed in your coronary arteries, giving a direct picture of the disease itself rather than the risk factors driving it. A high score can prompt more intensive treatment even when your blood results look reasonable. Our article on what a high calcium score really means explains how to interpret the number.

One genuine source of confusion deserves a mention. Because statins can convert soft plaque into denser, calcified plaque, people on a statin can sometimes see their calcium score rise even as their risk falls. This apparent paradox is explained in our piece on statins and your calcium score. For people who need a more detailed look at the arteries themselves, a CT coronary angiogram can show both calcified and soft plaque. Inflammation markers such as hs-CRP can add yet another dimension. Which of these, if any, is right for you depends entirely on your circumstances and is a decision for you and your cardiologist.

Where the Guidelines Stand

The official guidance reflects this balanced reality. Different expert bodies place apoB at slightly different points on the spectrum, but none has discarded LDL cholesterol.

Guideline body Position on apoB
European (ESC/EAS) Accepts apoB as an alternative to LDL cholesterol for risk assessment. The 2025 update still confirms LDL cholesterol as the primary target.
Canadian (CCS) The most apoB-forward. Allows apoB to be used as the primary therapeutic target, especially when triglycerides are raised.
United States (ACC/AHA) Lists a high apoB as a risk-enhancing factor that supports more intensive treatment, but does not yet set a routine apoB target.
National Lipid Association Proposes graded apoB targets that become stricter as cardiovascular risk rises.

The main reason apoB has not yet replaced LDL cholesterol everywhere is not weak evidence. It is the absence of a single agreed target across all guidelines, combined with a degree of caution about changing long-established practice. Availability and cost also vary from one health system to another.

Should You Add ApoB to Your Next Blood Test?

In Australia, apoB can be measured by most pathology laboratories, usually reported in grams per litre. It is not always part of a standard lipid panel and may not be routinely rebated, so it is worth asking whether it applies to your situation and whether there is an out of pocket cost.

There is a strong argument for measuring apoB at least once if you fall into a higher-risk group, particularly if you have raised triglycerides, type 2 diabetes, metabolic syndrome, or a family history of early heart disease. It is also useful when your LDL cholesterol seems well controlled but you or your cardiologist remain concerned about residual risk. For someone already tracking LDL, HDL, and lipoprotein(a), as many thoughtful patients now do, apoB is a natural and informative addition rather than a replacement for any of them.

What apoB cannot do is stand alone. It works best alongside your other blood results, any imaging you have had, and the broader picture of your risk factors. The number is only as useful as the conversation it prompts with the person managing your care.

Heart Matters Resource

When in Doubt, Get Checked Out

If you are unsure whether your cholesterol results tell the full story, a focused review of your numbers with your GP or cardiologist is one of the most worthwhile conversations you can have.

Read: When in Doubt, Get Checked Out →

Conclusion

ApoB is one of the most useful advances in everyday cardiovascular risk assessment, because it counts the particles that actually cause plaque rather than estimating the cholesterol they carry. For people whose standard cholesterol result may be quietly misleading, it can uncover risk that would otherwise go unnoticed.

The balanced takeaway is this. LDL cholesterol, triglycerides, and lipoprotein(a) each remain valuable, and apoB sharpens the picture rather than replacing any of them. None of these numbers stands alone, because heart disease is multifactorial: your blood pressure, diabetes, smoking status, weight, and family history all matter alongside your lipids. The most useful conversation you can have is not about a single number, but about the whole picture, with the cardiologist who knows your circumstances.

Related Reading

Vitamin K and Your Arteries: What the Evidence Shows

vitamin K
Key Points
  • A new randomised trial, VitaK-CAC, found that a daily vitamin K2 supplement (a form called MK-7) modestly slowed the build-up of calcium in the heart’s arteries over two years compared with a placebo.
  • The effect was small. Calcium scores still rose in both groups, but they rose less in the people taking vitamin K2. The annual increase was reduced by about 19 points on the standard calcium scoring scale.
  • The study was small, with 180 participants, and ran into delays, so the findings are best seen as a promising early signal rather than proof that supplements prevent heart attacks.
  • Independent experts urge caution. We do not yet know whether slowing the rise in a calcium score actually translates into fewer heart attacks or strokes, and there is even debate about whether calcified plaque is the dangerous kind.
  • Vitamin K can interfere with warfarin and other blood-thinning medications, so nobody on an anticoagulant should start a supplement without speaking to their doctor first.

For years, the question of whether vitamin K supplements can protect the heart has been long on theory and short on evidence. A new clinical trial has now offered the clearest signal yet, and the answer is a carefully qualified “possibly”.

The study, called VitaK-CAC, was published recently in JAMA Cardiology. It found that a daily vitamin K2 supplement slowed the progression of calcium build-up in the coronary arteries over two years. The result is genuinely interesting. It is also a long way from a recommendation that everyone should head to the pharmacy.

What the Study Looked At

Researchers in the Netherlands recruited 180 adults who already had some calcium in their coronary arteries, measured using a CT scan that produces a coronary calcium score. Everyone in the study had a score between 50 and 400, which represents mild to moderate calcification.

Half the group took a daily dose of a vitamin K2 supplement known as MK-7, also called menaquinone-7. The other half took an identical placebo, an inactive tablet with no medicine in it, sometimes called a sugar pill. Neither the participants nor the researchers knew who was taking which until the study ended. This kind of design is the gold standard in medical research, because it stops expectation alone from influencing the result. The participants returned every six months for two years so their calcium scores and vitamin K blood levels could be tracked.

MK-7 is a specific form of vitamin K2. It is favoured in research because the body absorbs it well and it stays in the bloodstream longer than the more common vitamin K1 found in leafy greens.

What They Found

Calcium scores rose in both groups over the two years, which is what usually happens as calcification is a gradual, ongoing process. The difference was in how much they rose.

19 points the estimated reduction in the yearly rise of coronary calcium score among people taking vitamin K2, compared with placebo. VitaK-CAC trial, JAMA Cardiology, 2026

At the start, the two groups had similar average calcium scores, around 135 and 145. By two years, the placebo group had climbed to 214, while the vitamin K2 group reached 184. The slower climb in the supplement group was statistically significant, meaning it was unlikely to be down to chance alone.

Blood tests confirmed the supplement was doing something measurable. Vitamin K2 levels rose sharply in the treatment group, and a protein involved in keeping calcium out of artery walls behaved differently between the two groups. The researchers calculated that the calcium score and the vitamin K2 treatment were the two strongest predictors of how calcification changed over time.

Why Calcium in the Arteries Matters

Calcium in bones and teeth is essential. In artery walls it is a marker of atherosclerosis, the gradual furring and stiffening of blood vessels that underlies most heart attacks and strokes. The higher the calcium score, the more plaque a person tends to have, and the higher their cardiovascular risk.

The idea behind vitamin K2 is that it activates proteins which help direct calcium towards bones and away from artery walls, the same mechanism we explored in our explainer on vitamins D3 and K2. VitaK-CAC is the first reasonably robust trial to suggest the theory might hold up in the coronary arteries themselves.

A promising early result is not the same as a proven treatment. This trial opens a door. It does not tell us to walk through it just yet.

Why Experts Are Urging Caution

The researchers themselves were measured about their findings, and independent commentators were more cautious still. There are several reasons to hold back.

The first is size and design. With 180 participants and a study that suffered delays, this is a small trial. Small studies can produce real findings, but they need to be repeated in larger groups before anyone can be confident the result is reliable.

The second is more subtle. A calcium score is normally used to measure how much plaque a person has, not as something we actively try to lower. We have strong evidence that a high score predicts higher risk, but very little evidence about what happens when you deliberately slow the score’s rise. Lowering the number is not automatically the same as lowering the danger.

There is even a debate about whether calcified plaque is the dangerous kind. Statins tend to stabilise plaque and can leave behind calcium as a sign of that stability, a counter-intuitive effect we cover in our article on statins and your calcium score. Some experts worry that reducing calcified plaque could leave more of the softer, rupture-prone plaque behind. Nobody yet knows whether that concern is real. The earlier Danish AVADEC trial, which tested vitamin K2 in people with calcified aortic valves, found no significant benefit, underlining how unsettled this field still is.

What This Means for You

If you have had a calcium score done and it showed mild calcification, this study is worth being aware of, but it does not change current advice. The trial’s own authors said they would want larger studies before recommending vitamin K2 in any guideline, and other specialists who reviewed the work agreed they are not yet advising it for their patients.

Vitamin K2 is available without prescription and appears safe for most people at the doses studied. That is partly why some of the researchers said they would not object to people trying it. Safe and available, however, is not the same as proven to prevent heart attacks.

The most important practical point is a safety one. Vitamin K plays a central role in blood clotting, and it directly interferes with warfarin and similar anticoagulant medications. Anyone taking a blood thinner should not start a vitamin K supplement, or make large changes to their intake of vitamin K-rich foods, without first discussing it with their doctor or anticoagulation clinic.

More broadly, what is right for one person is not automatically right for another. Whether a supplement suits you depends on your own health history, the other medicines you take, and any conditions you live with. A supplement that is harmless for one person can interact with medication or be unsuitable for another. Your GP, cardiologist, or pharmacist knows your individual circumstances and is the right person to tell you whether vitamin K2 is sensible, safe, and compatible with the rest of your care.

For everyone, the foundations of heart health have not shifted: not smoking, managing blood pressure and cholesterol, staying active, and understanding your own cardiovascular risk factors. A supplement, even a promising one, sits well behind those.

Heart Matters Resource

When in Doubt, Get Checked Out

A calcium score, a new supplement, or a question about your medications is always worth raising with a professional who knows your history. If you are unsure whether something applies to you, that is reason enough to ask.

Read: When in Doubt, Get Checked Out →

Conclusion

VitaK-CAC is a thoughtful, well-conducted small trial that has nudged a long-standing theory a step closer to reality. It suggests that vitamin K2 might slow the build-up of calcium in the coronary arteries, and that finding deserves to be taken seriously and tested further.

For now, the sensible position is curiosity rather than action. If vitamin K2 interests you, the best next step is a conversation with your own cardiologist, GP, or pharmacist, who can tell you whether it is right for you and compatible with any other medicines or conditions you have. The science here is moving, and it is worth watching, but the proven path to a healthier heart still runs through the well-established basics.

Related Reading

Right Bundle Branch Block (RBBB): Why It Sounds Worse Than It Usually Is

right bundle branch block RBBB
Key Points
  • A right bundle branch block, often shortened to RBBB, is an electrical finding on an ECG. It means the signal travelling to the right side of the heart takes a slightly slower route than usual. It is not a blocked artery.
  • On its own, in a person who feels well and has a healthy heart, RBBB is common and usually harmless. It is found in roughly 1 in 100 adults, and the figure rises with age.
  • What matters is the context. A longstanding RBBB in someone with no symptoms is very different from a brand new RBBB that appears alongside chest pain or breathlessness.
  • RBBB becomes more important when it is new, when it occurs with symptoms, or when it appears together with other electrical changes on the same ECG.
  • Most people with isolated RBBB need no treatment at all. The block itself is not something that gets fixed, and in the majority of cases it never causes a problem.

Of all the phrases that can appear on an ECG report, “right bundle branch block” is one that sends people straight to a search engine, usually with a rising sense of alarm. The word block sounds ominous. It brings to mind a blocked artery, or something serious going wrong with the heart’s plumbing.

In the great majority of cases, it is neither of those things. This article explains what a right bundle branch block actually is, why it shows up, when it is nothing to worry about, and the smaller number of situations where it genuinely matters.

What the Bundle Branches Actually Do

Your heart has its own electrical wiring. Each beat begins with a signal that spreads across the upper chambers, then passes through a junction box in the centre of the heart and down into the two large lower chambers, the ventricles, which do the heavy pumping work.

From that junction box, the signal travels down two main cables, one to the left ventricle and one to the right. These cables are the bundle branches. They split into ever-finer fibres so that the electrical signal reaches every part of the muscle at almost the same instant, allowing both ventricles to squeeze together in a single coordinated beat.

A right bundle branch block means the cable to the right ventricle is not carrying the signal normally. The impulse is delayed or has to take a detour, reaching the right ventricle a fraction of a second later than it should. The heart still beats. The right ventricle still contracts. It simply gets its instruction by a slightly slower path.

This is quite different from a coronary artery problem, where the issue is blood supply rather than electrical signalling. If you would like to see the wiring for yourself, our interactive guide to your heart’s conduction system shows how the signal travels from the heart’s natural pacemaker down through the bundle branches to the ventricles.

What RBBB Looks Like on an ECG, in Plain Language

An ECG is a recording of the electrical signals that pass through your heart with every beat. Each beat produces a series of waves on the trace, and each wave reflects a different stage of that beat. The first small wave, called the P wave, reflects the upper chambers being activated. The tall central spike, called the QRS, reflects the contraction of the ventricles. The rounded wave that follows, the T wave, reflects those chambers electrically resetting before the next beat.

Because RBBB delays the signal to one ventricle, the two chambers no longer squeeze in perfect unison. The QRS spike, which is normally narrow and sharp, becomes wider and often develops a second bump, giving it a distinctive shape that a cardiologist recognises instantly.

Normal beat

P QRS T

The QRS spike is narrow and sharp. Both ventricles are activated almost together.

Right bundle branch block

P QRS T

The QRS is wider and carries a second bump. This is the delayed right ventricle catching up.

How to read this: the spike in the middle, the QRS, is the part to watch. A normal one is narrow and sharp. In RBBB it is wider and usually has a notch, like an M shape, because the right side of the heart is activated a beat behind the left. The small waves either side are not the focus here.

Why Does a Right Bundle Branch Block Happen?

There are many reasons, and they sit on a wide spectrum from completely benign to clinically important.

A normal variant

In many healthy people, RBBB is simply how their wiring is built. It can be present for life, cause no symptoms, and never lead to any trouble.

Age and the wiring itself

The conduction fibres can slow gradually with age, in the same way other tissues change over time. This is why RBBB becomes more common in later decades.

Strain on the right heart

Conditions that make the right side of the heart work harder, such as some lung conditions, can be associated with RBBB. Here the block is a signpost, not the problem itself.

Heart muscle conditions

Some conditions affecting the heart muscle or its valves can disturb the conduction system and produce RBBB along the way.

After a heart procedure

RBBB can appear after certain cardiac procedures or surgery. When expected, it is usually monitored rather than treated, and most people do well.

A sign during a heart attack

A brand new RBBB that appears during chest pain can be an important warning sign. This is the context that needs urgent assessment, not a routine finding.

The Question That Really Matters: Is It New?

This is the single most useful thing to understand about a right bundle branch block. The pattern itself tells a cardiologist relatively little until it is placed in context, and the most important piece of that context is whether the block is new or longstanding.

A right bundle branch block that has been present on previous ECGs for years, in someone who feels well, is reassuring. It is part of that person’s normal electrical signature. Research consistently shows that isolated RBBB in people without other heart disease carries an excellent outlook.

A right bundle branch block that has appeared for the first time, particularly alongside symptoms such as chest pain, breathlessness, or fainting, is a different matter. Here the new block may be a clue that something is happening in the heart right now, and it deserves prompt evaluation. This is why your cardiologist will often be very interested in finding an old ECG to compare against.

RBBB and LBBB Are Not the Same Story

It is natural to assume that a block on the right and a block on the left are mirror images of each other, equally significant. In practice, they tend to carry different weight.

A left bundle branch block more often prompts a closer look at the heart muscle and its pumping function, because the left ventricle is the heart’s main pump. An isolated right bundle branch block, by contrast, is more frequently a benign finding in an otherwise healthy person.

This is a generalisation rather than a rule, and the context still governs everything. But it helps explain why a patient might be told their RBBB is nothing to worry about while a friend with an LBBB was sent for more tests.

Will I Have Symptoms?

Most people with a right bundle branch block have no symptoms from it whatsoever. They feel completely normal, and the finding is picked up by chance on an ECG done for an unrelated reason, such as a routine check, a pre-operative assessment, or an insurance examination.

Because RBBB itself rarely causes symptoms, any symptoms that are present, such as breathlessness, palpitations, or fainting, usually point to whatever underlying condition is present rather than to the block on its own. That is part of why your cardiologist treats the symptoms and the whole clinical picture, not the line on the ECG report.

What Happens Next, and What Tests Might Be Done

If an isolated RBBB is found and you feel well, often the answer is simply that nothing further is needed beyond noting it on your record. Knowing it is there is valuable in itself, because it gives every future ECG a baseline to compare against.

When the context suggests a closer look is worthwhile, your cardiologist may arrange an echocardiogram, an ultrasound scan that shows the heart’s structure and how well it is pumping. This helps confirm whether the heart muscle and valves are normal. Depending on the situation, blood tests or a period of heart rhythm monitoring may also be suggested.

The point of these tests is not the block itself, which generally cannot and need not be reversed. It is to make sure there is nothing else going on that the RBBB might be pointing to.

When RBBB Sits Alongside Other Findings

One situation deserves a mention because it changes the picture. Sometimes RBBB appears on an ECG together with other conduction delays. When the heart’s electrical pathways show several areas of slowing at once, cardiologists pay closer attention, because the wiring is showing wear in more than one place.

In a small number of people, particularly those who also have symptoms such as fainting, this combination may eventually lead to a conversation about a pacemaker. This is the exception rather than the rule, and it applies to a minority of cases. The great majority of people with a simple, isolated RBBB never approach this territory.

Heart Matters Resource

When in Doubt, Get Checked Out

A new finding on an ECG, or one that comes with chest pain, breathlessness, or fainting, is always worth discussing promptly with your GP or cardiologist rather than worrying about alone.

Read: When in Doubt, Get Checked Out →

Conclusion

A right bundle branch block is an electrical finding, not a blocked artery, and for most people who carry one it is a harmless quirk of their heart’s wiring that will never cause a problem. The word block makes it sound far more alarming than it usually is.

What turns a routine finding into one worth investigating is context: whether it is new, whether it comes with symptoms, and whether it sits alongside other changes. If your ECG shows a right bundle branch block and you feel well, the most likely explanation is the most reassuring one. If it is new or you have symptoms, it is worth discussing with your cardiologist promptly, who can place that single line on the report into the bigger picture of your heart.

Related Reading

Stay Informed

The latest heart health news, research and resources — delivered to your inbox.